Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 402 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tacrolimus/MMF Clear all

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus; Procedure · Drug · Biological
Lead sponsor: Srinivas Devarakonda; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: BK Viremia, BK Nephropathy
Interventions: Tacrolimus, Mycophenolate acid, Sirolimus; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: New York, New York

Conditions: Renal Transplantation
Interventions: sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Ann Arbor, Michigan + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Liver Transplantation
Interventions: Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Kidney Transplantation
Interventions: Rabbit Antithymocyte Globulin, Velcade, Rituxan; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Severe Aplastic Anemia
Interventions: umbilical cord blood (UCB); Genetic
Lead sponsor: West Virginia University; Other
Eligibility: 16 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hematologic Neoplasms
Interventions: Omission of the drug mycophenolate mofetil; Other
Lead sponsor: Ronald Paquette; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Transplantation
Interventions: Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus; Procedure · Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Transplant; Failure, Kidney, EBV
Interventions: belatacept, Tacrolimus, MPA; Drug
Lead sponsor: Lorenzo Gallon; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
Interventions: Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant; Drug · Radiation · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Uveitis
Interventions: Adalimumab (ADA), Conventional immunosuppression (CON); Biological · Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 13 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 14 more

Conditions: Secondary Myelofibrosis
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine, Glycosylated Recombinant Human G-CSF AVI-014, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions: Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more

Conditions: Hematologic Malignancy
Interventions: melphalan, fludarabine, thiotepa, Cyclophosphamide, Mesna, Mycophenolate Mofetil, Filgrastim, Tacrolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection; Biological · Drug · Radiation + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity); Drug
Lead sponsor: Targazyme, Inc.; Industry
Eligibility: 1 Year to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more

Conditions: Adult Primary Kidney Transplantation
Interventions: Tacrolimus/Sirolimus, Tacrolimus/MMF, Neoral/Sirolimus; Drug
Lead sponsor: University of Miami; Other
Eligibility: 16 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Transplant; Failure, Kidney
Interventions: Alemtuzumab, Daclizumab, Thymoglobulin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Graft-versus-host-disease
Interventions: INCA034176, Best available Treatment (BAT); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 9 more

Conditions: GATA2, Immunodeficiency, MDS
Interventions: Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories), Busulfan (Busulfex), Cyclophosphamide (CTX, Cytoxan), Total Body Irradiation (TBI), Mycophenolate mofetil (MMF), Tacrolimus, Equine Anti-Thymocyte Globulin; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 6 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Cirrhosis, Liver Transplant Disorder
Interventions: Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 72 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Using mTOR Inhibitors in the Prevention of BK Nephropathy

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Unrelated Umbilical Cord Blood (UBC)Transplantation

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Belatacept 3 Month Post Transplant Conversion Study

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Alloantibodies in Pediatric Heart Transplantation

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Steroid Free Immunosuppression in Liver Transplantation